GLP-1 dosing reference.

1. 0.25 mg/wk × 4 wks
2. 0.5 mg/wk × 4 wks
3. 1 mg/wk × 4 wks
4. 1.7 mg/wk × 4 wks
5. 2.4 mg/wk maintenance

Slow titration mitigates GI side effects. Discontinue if max dose not tolerated.

1. 0.25 mg/wk × 4 wks
2. 0.5 mg/wk × ≥4 wks
3. 1 mg/wk × ≥4 wks
4. 2 mg/wk maintenance

0.25 mg dose is titration only — not therapeutic for glycemic control.

1. 3 mg PO daily × 30 days
2. 7 mg PO daily × 30 days
3. 14 mg PO daily maintenance

Take fasting, ≥30 min before first food/drink with ≤4 oz plain water. Lower bioavailability than SC.

1. 2.5 mg/wk × 4 wks
2. 5 mg/wk × 4 wks
3. 7.5 mg/wk × 4 wks
4. 10 mg/wk × 4 wks
5. 12.5 mg/wk × 4 wks
6. 15 mg/wk maintenance

Dual GLP-1/GIP agonist. Higher mean weight loss than semaglutide in SURMOUNT-1.

1. 2.5 mg/wk × 4 wks
2. 5 mg/wk maintenance
3. ↑ by 2.5 mg q4wks PRN
4. up to 15 mg/wk

Same molecule as Zepbound; T2DM indication only on this label.

1. 0.6 mg/day × 1 wk
2. 1.2 mg/day × 1 wk
3. 1.8 mg/day × 1 wk
4. 2.4 mg/day × 1 wk
5. 3 mg/day maintenance

Discontinue if patient cannot tolerate 3 mg dose; lower-dose regimens have insufficient efficacy data.

1. 0.6 mg/day × 1 wk
2. 1.2 mg/day × ≥1 wk
3. 1.8 mg/day if needed

1. 0.75 mg/wk
2. ↑ to 1.5 mg/wk after ≥4 wks
3. ↑ to 3 mg/wk PRN
4. up to 4.5 mg/wk

No mealtime constraint. Single-use pen with hidden needle.

1. 5 mcg BID × ≥1 mo
2. ↑ to 10 mcg BID

Inject within 60 min before morning + evening meals. Older agent; less commonly initiated.

1. 2 mg/wk maintenance (no titration)

Extended-release suspension. Resuspend by tapping vigorously before injection.

1. Patient-specific. Common compounded titration mirrors Wegovy schedule.
2. Verify with prescribing pharmacy.

NOT FDA-reviewed. Post-shortage status: see /guides/compounded-glp1-post-enforcement-2026.

1. Patient-specific. Common compounded titration mirrors Zepbound schedule.
2. Verify with prescribing pharmacy.

NOT FDA-reviewed. May include adjuvants (B12, etc.) not in FDA-approved formulation.